AboutContact usRSS
dotsbydots
SEARCHCONTACT US

Buzz

Most popular

Daily
Weekly
1
Wiz acquires Dazz for $450 million to strengthen AI-driven cloud security
2
Cyera doubles valuation to $3B with $300M Series D, total funding hits $600M in seven months
3
Claroty veterans launch Twine with $12M in Seed funding from Dell and Wiz founders to deploy AI cyber workers
4
Mediaocean acquires Innovid for $500M, delisting it from the NYSE
5
Prompt Security raises $18 million Series A to protect enterprises from GenAI risks
More news

Royalties

7 stories about Royalties
עומר אדם זמר ב הופעה ב פארק הירקון תל אביב

Israeli Pop Star Wants a Bite out of Spotify, YouTube

02.01.20|Avior Abou
Omer Adam is one of Israel’s most successful musicians, currently topping Spotify Israel’s best-played list
כנס שטכנולוגיה ומוסיקה נפגשים אלאין פריסקר

Royalty Distribution Startup Revelator Launching Mobile Payment App for Musicians

04.06.19|Meir Orbach
The application enables musicians to cash out royalties at any given time once a song has been streamed or played on the radio
eMusic CEO Tamir Koch

Online Music Service eMusic Plans $70 Million ICO to Pivot to Blockchain

31.07.18|Lilach Baumer
eMusic is a niche player offering subscription-based download of mainly indie, classical and jazz artists and labels
פרופסור זליג אשחר

Scientist Quarrel Over Kite Pharma Sale Royalties to be Settled Out of Court

28.05.18|Zohar Shahar Levy
Israeli immunologist Zelig Eshhar, who holds the patent for Kite Pharma’s anti-cancer technology, has been sued by a former student for infringement of patent rights
כיל ים המלח ICL Dead Sea

After 78 Years, Israel May Extend Dead Sea Mining Rights to Non-Israeli Companies

24.01.18|Omri Milman and Lilach Baumer
The current permit held by Israel-based ICL will expire in 2030. A government draft proposal recommends allowing non-Israeli entities to participate in a future tender
פרופסור זליג אשחר

Immunologists Exchange Verbal Blows in Legal Fight Over Kite Pharma Windfall

26.12.17|Zohar Shahar Levy
In August, Gilead Science bought anti-cancer treatment company Kite Pharma for $11.9 billion. Two Israeli scientists involved in the early research that led to the company’s breakthrough are now quarreling over patent royalty payments
default image

University Retracts Mobileye Equity Claims

07.09.17|Sefi Krupsky
After skirmish with star scientist, the Hebrew University backs down